Medical and endovascular treatments of symptomatic intracranial stenosis. A Bayesian network meta-analysis.


Journal

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
ISSN: 1532-2653
Titre abrégé: J Clin Neurosci
Pays: Scotland
ID NLM: 9433352

Informations de publication

Date de publication:
May 2019
Historique:
received: 08 04 2018
revised: 04 01 2019
accepted: 28 01 2019
pubmed: 13 2 2019
medline: 30 5 2019
entrez: 13 2 2019
Statut: ppublish

Résumé

Intracranial stenosis is a well-established stroke risk factor with an increase of stroke recurrence or TIA up to 12.6% at 1 year. Treatments are different: medical and endovascular. We performed a multiple treatment comparison analysis to detect the best treatment in reducing the risk of stroke recurrence. We searched in Medline, Embase, Cochrane Central Register of Controlled Trials databases between 1979 and October 2017. Inclusion criteria were prospective randomized trials that evaluated patients with TIA or stroke due to intracranial stenosis and treated with different medical therapies and/or endovascular procedures. Primary endpoint was the recurrence of TIA or stroke in the territory of intracranial stenosis, while secondary endpoint was represented by any stroke or vascular death. Multiple treatment comparison meta-analysis based on a Bayesian fixed and random effects Poisson model was performed. Seven trials were included with a total of 1337 patients. At multiple treatment comparison, no significant differences between treatments were observed for both primary (median fixed effect standard OR: 0.40; 95%CI: 0.02-1.07) and secondary endpoints (median random effect standard OR: 1.17; 95%CI: 0.32-1.92). Treatment with aspirin alone ranked with high values both for primary and secondary endpoints (surface under the cumulative ranking curve of 70% and 82%, respectively). In patients with symptomatic intracranial stenosis, no differences between treatments were observed. However, aspirin alone was more effective than stenting in the reduction of TIA or stroke recurrences, with a better safety profile than oral anticoagulants.

Identifiants

pubmed: 30745129
pii: S0967-5868(18)30617-9
doi: 10.1016/j.jocn.2019.01.040
pii:
doi:

Substances chimiques

Anticoagulants 0
Aspirin R16CO5Y76E

Types de publication

Comparative Study Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

84-90

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

S Vidale (S)

Department of Neurology & Stroke Unit, Sant'Anna Hospital, Como, Italy. Electronic address: simone.vidale@asst-lariana.it.

E Agostoni (E)

Department of Neurology, Niguarda Ca' Granda Hospital, Milan, Italy.

G Grampa (G)

Department of Neurology & Stroke Unit, Sant'Anna Hospital, Como, Italy.

A Consoli (A)

Service de Neuroradiologie Diagnostique et Thérapeutique, Hopital Foch, Paris, France; Interventional Neurovascular Unit, Careggi University Hospital, Florence, Italy.

D Consoli (D)

Department of Neurology, "G. Jazzolino" Hospital, Vibo Valentia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH